This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Pacemakers/ Defibrillators  • Cardiovascular System  • Congestive Heart Failure/ Cardiomyopathy  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

How Low the Bar?

Rick A. Nishimura, MD; Steve R. Ommen, MD

JAMA. 2007;298:452-454.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hypertrophic cardiomyopathy (HCM) is a relatively common disorder (occurring in approximately 1 in 500 adults in the general population)^1-2 and has the widely recognized clinical findings of massive myocardial hypertrophy and dynamic left ventricular outflow tract obstruction. Once thought to be a disease of unknown etiology, HCM is now recognized as a genetic disorder often caused by a mutation in at least 1 of 12 genes that encode the proteins of the cardiac sarcomere.³

Knowledge about HCM has changed dramatically over the past few decades, by virtue of increased recognition of this disorder due to heightened awareness of the disease and wider use of noninvasive imaging modalities. Initially, HCM was thought to be a deadly disease of the young, because patients presented with severely limiting symptoms (dyspnea, angina, and syncope) or even sudden cardiac death.⁴ However, patients with HCM can present with . . . [Full Text of this Article]

Author Affiliations: Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Barry J. Maron, Paolo Spirito, Win-Kuang Shen, Tammy S. Haas, Francesco Formisano, Mark S. Link, Andrew E. Epstein, Adrian K. Almquist, James P. Daubert, Thorsten Lawrenz, Giuseppe Boriani, N. A. Mark Estes, III, Stefano Favale, Marco Piccininno, Stephen L. Winters, Massimo Santini, Sandro Betocchi, Fernando Arribas, Mark V. Sherrid, Gianfranco Buja, Christopher Semsarian, and Paolo Bruzzi
JAMA. 2007;298(4):405-412.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sudden cardiac death risk in hypertrophic cardiomyopathy
Ommen and Gersh
Eur Heart J 2009;30:2558-2559.
FULL TEXT  

Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram.
McLeod et al.
J Am Coll Cardiol 2009;54:229-233.
ABSTRACT | FULL TEXT  

Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy
Lin et al.
Heart 2009;95:709-714.
ABSTRACT | FULL TEXT  

Implantable defibrillators in hypertrophic cardiomyopathy
Grace
Heart 2009;95:695-696.
FULL TEXT  

Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy
Saumarez et al.
Eur Heart J 2008;29:1653-1661.
ABSTRACT | FULL TEXT  

Non-invasive risk stratification in hypertrophic cardiomyopathy: don't throw out the baby with the bathwater
Sen-Chowdhry and McKenna
Eur Heart J 2008;29:1600-1602.
FULL TEXT  

Oral Disopyramide for the Acute Treatment of Severe Outflow Obstruction in Hypertrophic Cardiomyopathy in the ICU Setting
Sirak and Sherrid
Chest 2008;133:1243-1246.
ABSTRACT | FULL TEXT  

Do ICDs Reduce the Risk for Sudden Death in Patients with HCM?
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT